OptiNose US Inc (OPTN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8225
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OptiNose US Inc (OptiNose) is a specialty pharmaceutical company that develops and delivers new pipeline drugs through intranasal deposition of medications. The company offers products such as XHANCE fluticasone propionate and ONZETRA sumatriptan nasal powder. Its products are used in the therapeutic areas of nasal inflammatory diseases, nasal congestion and obstruction, chronic rhinosinusitis, facial pain and pressure, drainage and postnasal drip, nasal polyps, autism, narcolepsy and Parkinson’s diseases. OptiNose develops powder delivery device with a disposable drug-containing section and liquid delivery device for medication-carrying airflow into nasal cavity. The company also develops exhalation delivery system technology used for the treatment of neurological or psychiatric disorders, and central nervous system disorders. It has operations in the US, Norway and the UK. OptiNose is headquartered in Yardley, Pennsylvania, the US.

OptiNose US Inc (OPTN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OptiNose US Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
OptiNose Raises USD37 Million in Series D Financing 11
Optinose Raises USD30 Million in Venture Financing 12
Private Equity 13
Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 13
Partnerships 15
OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 15
Equity Offering 16
Optinose Raises USD55.6 Million in Public Offering of Share 16
Optinose to Raise Funds through Public Offering of Shares 18
OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 19
OptiNose Raises USD138 Million in IPO of Shares 20
Debt Offering 22
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23
OptiNose US Inc – Key Competitors 24
OptiNose US Inc – Key Employees 25
OptiNose US Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 14, 2018: Optinose reports second quarter 2018 financial results and recent operational highlights 27
May 14, 2018: Optinose Announces First Quarter 2018 Financial Results 29
Mar 13, 2018: Optinose Announces Fourth Quarter and Full Year 2017 Financial Results 31
Nov 27, 2017: Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights 33
Corporate Communications 35
Feb 22, 2018: Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee 35
Feb 09, 2017: OptiNose appoints chief legal officer 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
OptiNose US Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OptiNose US Inc, Deals By Therapy Area, 2012 to YTD 2018 8
OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OptiNose Raises USD37 Million in Series D Financing 11
Optinose Raises USD30 Million in Venture Financing 12
Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 13
OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 15
Optinose Raises USD55.6 Million in Public Offering of Share 16
Optinose to Raise Funds through Public Offering of Shares 18
OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 19
OptiNose Raises USD138 Million in IPO of Shares 20
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23
OptiNose US Inc, Key Competitors 24
OptiNose US Inc, Key Employees 25
OptiNose US Inc, Subsidiaries 26

List of Figures
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[OptiNose US Inc (OPTN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Koninklijke Philips N.V. (PHIA)-医療機器分野:企業M&A・提携分析
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company which focuses on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The company develops and manufactures medical …
  • Lassonde Industries Inc.:企業の戦略・SWOT・財務情報
    Lassonde Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary Lassonde Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Zimmer Biomet Holdings Inc (ZBH):企業の財務・戦略的SWOT分析
    Zimmer Biomet Holdings Inc (ZBH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Orkuveita Reykjavikur:電力:M&Aディール及び事業提携情報
    Summary Orkuveita Reykjavikur (Orkuveita) is a public utility company that provides electricity and water. The company generates and supplies electricity. It harnesses hot water from geothermal fields and supplies it for heating applications. The company also supplies cold water from its groundwater …
  • Ocado Group Plc:企業の戦略・SWOT・財務分析
    Ocado Group Plc - Strategy, SWOT and Corporate Finance Report Summary Ocado Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • ONEOK Partners LP:石油・ガス:M&Aディール及び事業提携情報
    Summary ONEOK Partners, L.P. (ONEOK Partners), a subsidiary of Oneok, Inc., is a midstream energy company. The company carries out gathering, processing, and storage and transportation of natural gas. It operates through master limited partnerships. ONEK Partners owns natural gas liquids (NGL) syste …
  • Airbus SAS:戦略・SWOT・企業財務分析
    Airbus SAS - Strategy, SWOT and Corporate Finance Report Summary Airbus SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Henry Schein Inc (HSIC)-製薬・医療分野:企業M&A・提携分析
    Summary Henry Schein, Inc. (Henry Schein) is a distributor of healthcare products and services. Its product and service portfolio consists of dental products, medical products, animal health products, software and technology and other value-added services. It offers generic and branded pharmaceutica …
  • Seaboard Corporation:企業の戦略・SWOT・財務情報
    Seaboard Corporation - Strategy, SWOT and Corporate Finance Report Summary Seaboard Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Brown Advisory Inc:企業の戦略・SWOT・財務分析
    Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report Summary Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Filtronic plc:企業の戦略・SWOT・財務情報
    Filtronic plc - Strategy, SWOT and Corporate Finance Report Summary Filtronic plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • IMI plc:企業の戦略・SWOT・財務分析
    IMI plc - Strategy, SWOT and Corporate Finance Report Summary IMI plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • KDDI Corporation:企業の戦略・SWOT・財務分析
    KDDI Corporation - Strategy, SWOT and Corporate Finance Report Summary KDDI Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Prognomix Inc:企業の製品パイプライン分析
    Summary Prognomix Inc (Prognomix) is a personalized medicine company that develops molecular diagnostic test for detection of risks to develop renal, ocular, cardiac, cerebral, vascular and other complications of diabetic disease. The company’s products include PGX IR01, PGx GR01, PGx CD01, PGx IR02 …
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Glaukos Corp (GKOS):企業の財務・戦略的SWOT分析
    Summary Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such …
  • ARC Document Solutions Inc (ARC):企業の財務・戦略的SWOT分析
    Summary ARC Document Solutions Inc (ARC), formerly American Reprographics Company is a provider of technology and document solutions. The company’s services comprise onsite managed print services, construction document and information management, archiving and information management, and sale of web …
  • Endesa SA (ELE):電力:M&Aディール及び事業提携情報
    Summary Endesa SA (Endesa), a subsidiary of Enel SpA, is an electric utility. It generates, distributes, and sells electricity. The company produces electricity in hydro, thermal, nuclear, combined cycle, and renewable and cogeneration plants. Endesa also supplies electricity and gas, and provides o …
  • Kurumoch International Airport:企業の戦略・SWOT・財務情報
    Kurumoch International Airport - Strategy, SWOT and Corporate Finance Report Summary Kurumoch International Airport - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Animal Health International Inc:企業の戦略的SWOT分析
    Animal Health International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆